NKF 2010 Anemia Coverage - Renal and Urology News

If not, please take a few moments to fill out the form below. It’s free, and ensures that you receive regular alerts to the latest clinical news and other content.

Email*

Password*

Keep me logged in Forgot your password?

Email*

Repeat Injections of Ferumoxytol Well Tolerated

Jody A. Charnow April 17, 2010

Ferumoxytol, a novel IV iron replacement therapy for CKD patients with iron deficiency anemia, is well tolerated regardless of the number of injections or interval between injections.

Iron Deficiency Common in CKD Patients

Jody A. Charnow April 17, 2010

Researchers who studied a group of non-dialysis CKD patients found that about one quarter of them suffered from iron deficiency anemia.

Study Explores Novel Markers of CKD Anemia

Jody A. Charnow April 17, 2010

Mitochondrial DNA copy number (mtDNA) and plasma levels of hepcidin hold promise as novel markers of anemia in CKD patients, suggest data introduced at the National Kidney Foundation's 2010 Spring Clinical Meetings.

Hemoglobin Levels Declining in CKD Patients on ESAs

Jody A. Charnow April 16, 2010

Hemoglobin (Hb) levels in non-dialysis CKD patients treated with erythropoiesis-stimulating agents (ESAs) have been on the decline.

Vitamin D May Lower EPO Requirements

Jody A. Charnow April 16, 2010

Administration of ergocalciferol (vitamin D2) to anemic hemodialysis (HD) patients receiving erythropoietin (EPO) may decrease EPO requirements, suggest data presented at the National Kidney Foundation 2010 Spring Clinical Meetings.

Researchers Report Advantages of Switching Anemia Treatments

Jody A. Charnow April 16, 2010

Anemic pre-dialysis CKD patients who were switched from darbepoetin to epoetin alfa (EPO) maintained similar hemoglobin levels but at a lower cost, according to a study presented at the National Kidney Foundation's 2010 Spring Clinical Meetings.

ESA Resistance Linked to Variant Hemoglobin in African Americans

Jody A. Charnow April 15, 2010

Variant hemoglobin phenotypes, including sickle cell trait and hemoglobin C trait, may be associated with resistance to treatment with erythropoietin-stimulating agents (ESAs) among African Americans with end-stage renal disease (ESRD).

IV Iron Doses Higher for HD Patients Hospitalized for Infections

Jody A. Charnow April 15, 2010

Hemodialysis (HD) patients hospitalized for infections receive significantly higher amounts of replacement IV iron therapy and cumulative iron dose, according to findings presented here at the National Kidney Foundation 2010 Spring Clinical Meetings.

Iron Lowers Platelet Counts

Jody A. Charnow April 15, 2010

ORLANDO, Fla.—Correcting iron deficiency in non-dialysis CKD patients lowers platelet counts and improves erythropoiesis, researchers reported here at the National Kidney Foundation's 2010 Spring Clinical Meetings.